Compared to control group, treated mice showed a 62% reduction of tumor area at the injection site (Fig. 4f), a 43% reduction of the PH3 index within the tumor mass (Fig. 4g), and an 18% reduction of Gfap immunoreactivity in the peritumoral area (Fig. 4h). The gene discussed is GFAP; the disease is neoplasm.